CASI Pharmaceuticals Inc
CASI
查看详细走势图
0.810USD
-0.021-2.59%
收盘 12/19, 16:00（美东）报价延迟15分钟
12.55M总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
-2.59%
5天
-6.14%
1月
-31.93%
6月
-38.87%
今年开始到现在
-71.38%
1年
-69.43%
查看详细走势图
TradingKey CASI Pharmaceuticals Inc股票评分
单位: USD 更新时间: 2025-12-19操作建议
CASI Pharmaceuticals Inc当前公司基本面数据相对非常健康，增长潜力很大。当前估值合理，在药品行业排名97/158位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价4.00。中期看，股价处于下降通道。近一个月，市场表现非常差，但公司基本面和技术面得分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
CASI Pharmaceuticals Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
分析师目标
根据
1
位分析师
买入
评级
4.000
目标均价
+330.11%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
CASI Pharmaceuticals Inc亮点
亮点风险
CASI Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing therapeutics and pharmaceutical products in China, the United States, and throughout the world. The Company is focused on acquiring, developing, and commercializing products that augment its hematology oncology therapeutic focus as well as other areas of unmet medical need. Its commercial product, EVOMELA, is an intravenous formulation of melphalan commercialized by Acrotech in the multiple myeloma treatment setting in the United States. Its pipeline products include CNCT19 (CD19 CAR-T), BI-1206 (anti- FcYRIIB antibody), CB-5339 (VCP/p97 inhibitor), CID-103 (Anti-CD38 Mab), Thiotepa, and Octreotide LAI. The Company’s Food and Drug Administration (FDA)-approved generic products for the China market include Entecavir tablets, Tenofovir disoproxil fumarate (TDF) tablets, Cilostazol tablets-50mg, Cilostazol tablets-100mg, Ondansetron HCL tablets, and Tizanidine tablets.
业绩增长期
公司处于发展阶段，最新年度总收入28.54M美元
估值高估
公司最新PE估值-0.27，处于3年历史高位
詹姆斯·西蒙斯持仓
明星投资者詹姆斯·西蒙斯持仓，最新持仓市值43.90K
活跃度增加
近期活跃度增加，过去20天平均换手率12.46
CASI Pharmaceuticals Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
CASI Pharmaceuticals Inc简介
CASI Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing therapeutics and pharmaceutical products in China, the United States, and throughout the world. The Company is focused on acquiring, developing, and commercializing products that augment its hematology oncology therapeutic focus as well as other areas of unmet medical need. Its commercial product, EVOMELA, is an intravenous formulation of melphalan commercialized by Acrotech in the multiple myeloma treatment setting in the United States. Its pipeline products include CNCT19 (CD19 CAR-T), BI-1206 (anti- FcYRIIB antibody), CB-5339 (VCP/p97 inhibitor), CID-103 (Anti-CD38 Mab), Thiotepa, and Octreotide LAI. The Company’s Food and Drug Administration (FDA)-approved generic products for the China market include Entecavir tablets, Tenofovir disoproxil fumarate (TDF) tablets, Cilostazol tablets-50mg, Cilostazol tablets-100mg, Ondansetron HCL tablets, and Tizanidine tablets.
公司代码CASI
公司CASI Pharmaceuticals Inc
CEOHe (Wei-Wu)
网址https://www.casipharmaceuticals.com/
常见问题
CASI Pharmaceuticals Inc(CASI)的当前股价是多少？
CASI Pharmaceuticals Inc(CASI)的当前股价是 0.810。
CASI Pharmaceuticals Inc的股票代码是什么？
CASI Pharmaceuticals Inc的股票代码是CASI。
CASI Pharmaceuticals Inc股票的52周最高点是多少？
CASI Pharmaceuticals Inc股票的52周最高点是3.470。
CASI Pharmaceuticals Inc股票的52周最低点是多少？
CASI Pharmaceuticals Inc股票的52周最低点是0.801。
CASI Pharmaceuticals Inc的市值是多少？
CASI Pharmaceuticals Inc的市值是12.55M。
CASI Pharmaceuticals Inc的净利润是多少？
CASI Pharmaceuticals Inc的净利润为-39.26M。
现在CASI Pharmaceuticals Inc(CASI)的股票是买入、持有还是卖出？
根据分析师评级，CASI Pharmaceuticals Inc(CASI)的总体评级为买入，目标价格为4.000。
CASI Pharmaceuticals Inc(CASI)股票的每股收益（EPS TTM）是多少
CASI Pharmaceuticals Inc(CASI)股票的每股收益（EPS TTM）是-3.023。
相关品种
